ClinicalTrials.gg
CompletedNCT00773734Updated May 7, 2020Results posted

Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)

A Phase 2 interventional study of Apremilast 10mg and Apremilast 20mg in Psoriasis and Plaque-type Psoriasis, sponsored by Amgen. Completed at 35 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-07.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
352
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing apremilast in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. apremilast · Psoriasis.

Enrollment
7th of 44
352 · median 103
Started
2008
the only one that year
Phase 2
10 of 44
none open now
Registered
4th of 44
by date
Lead sponsor
25 of 44
Amgen

Among the 44 studies testing apremilast in Psoriasis, this one is the 7th largest by enrollment, is the only one that started in 2008, is one of 10 in phase 2, and was the 4th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 44 studies testing apremilast in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About apremilast

apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing apremilast in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study was to test if the drug apremilast was safe, if it helped improve psoriasis, and how well the participants tolerated it.

Read the detailed description

This study fully explored the extent of treatment benefit achieved with doses of apremilast up to 30 mg by mouth (PO) twice daily (BID) with treatment duration for up to 6 months. In addition, it was important to determine the minimally effective dose for apremilast and more fully elucidate the dose response curve in this patient population. The results from this study helped guide the selection of the dose in the phase 3 trials.

Participants meeting eligibility criteria at the Baseline Visit (Week 0) were centrally randomized with the use of a permuted-block randomization list, with equal allocation to each of the four treatment arms: 10 mg, 20 mg or 30 mg PO BID of apremilast or placebo. In an effort to mitigate the dose-dependent adverse effects of apremilast (e.g., headache or gastrointestinal disturbances), participants had their dose titrated over a 7-day period (Days 1 through7). Participants received 10 mg PO BID of apremilast or identically-appearing placebo during Days 1 to 2. Participants randomized to the 10 mg BID dose continued taking this dose throughout the treatment phase of the study. Those participants randomized to the 20 mg BID dose were dose titrated to 20 mg PO BID of apremilast or identically-appearing placebo during Days 3 to 4 of dosing. Participants randomized to the 20 mg BID dose continued taking this dose throughout the treatment phase of the study. Those participants randomized to the 30 mg BID dose were dose titrated to 30 mg PO BID of apremilast or identically-appearing placebo during Days 5 to 7 and continued taking this dose throughout the treatment phase of the study. At Week 16, all participants originally randomized to the placebo arm were re-randomized to 20 mg BID or 30 mg BID of apremilast. All participants (i.e., those that were continuing their Apremilast dosing regimen, as well as those that were switched from placebo to apremilast) received drug at Week 16 in a treatment arm in a blinded fashion. In addition, participants who transitioned from placebo to active medication at Week 16 completed a dose titration schedule to help mitigate any potential GI side effects that may have jeopardized the blinding of the treatment arms.

At Week 24 (end of core study and beginning of an extension study), participants were given the option to enroll into an extension study (PSOR-005E NCT00953875) and continue on the same apremilast dosage they had received at the end of the core study, during Weeks 24-52, a total of 28 weeks. Participants who elected not to enter into the treatment extension study, completed a 4-week observational follow-up phase of the core study. At Week 52 (end of extension study and beginning of a long-term extension study), participants were given the option to enroll into a long term extension study (PSOR-005LTE NCT01130116), for 4 additional years. Participants who were treated with apremilast 10 mg BID in the extension study were randomly assigned and dose titrated to either apremilast 20 mg BID or 30 mg BID. Participants who were dosed with 20mg or 30 mg BID in the extension study continued to receive the same dose in the long-term extension study. The long-term extension study is anticipated to complete in May 2016.

03

Conditions studied

  • Psoriasis
  • Plaque-type Psoriasis

Browse trials for

Keywords

  • moderate-to-severe plaque-type psoriasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Understand and voluntarily sign an form
  • ≥18 years of age at the time of signing the informed consent form
  • Able to adhere to the study visit schedule and other protocol requirements.
  • Diagnosis of chronic, stable plaque psoriasis at least 6 months prior to screening as defined by:

    1. PASI (Psoriasis Area and Severity Index) score ≥ 12
    2. Body Surface Area (BSA) ≥ 10%
  • Candidate for photo/systemic therapy
  • In good health as judged by the investigator, based on medical history, physical examination, 12-lead (ECG), serum chemistry, hematology, immunology, and urinalysis
  • Meet all laboratory criteria as defined per protocol
  • Females of (FCBP) must have a negative urine pregnancy test at screening (Visit 1). In addition, sexually active FCBP must agree to use TWO of the following adequate forms of methods. A FCBP must agree to have pregnancy tests every 4 weeks while on study medication
  • Males (including those who have had a vasectomy) must agree to use barrier contraception (latex condoms) when engaging in reproductive sexual activity with FCBP while on study medication and for 84 days after taking the last dose of study medication

Exclusion criteria

Exclusion Criteria:

  • History of disease (as determined by the investigator)
  • Pregnant or breastfeeding
  • History of active mycobacterial infection within 3 years
  • History of (HIV) infection
  • Congenital and acquired immunodeficiencies
  • surface antigen positive or Hepatitis B core antibody positive at screening
  • Antibodies to at screening
  • or history of malignancy except for treated [i.e., cured] basal-cell skin carcinomas
  • Any condition, including the presence of laboratory abnormalities, that places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
  • Psoriasis flare within 4 weeks of screening
  • Topical therapy within 2 weeks of randomization
  • Systemic therapy for psoriasis within 4 weeks of randomization
  • Use of phototherapy within 4 weeks of randomization [(i.e., Ultraviolet (UVB), Psoralens and long-wave ultraviolet radiation (PUVA)]
  • Adalimumab, etanercept, efalizumab or infliximab within 12 weeks of randomization
  • Alefacept within 24 weeks of randomization
  • drug within 4 weeks of randomization, or 5 pharmacokinetic/pharmacodynamic half lives, if known (whichever is longer)
  • Prolonged sun exposure or use of tanning booths or other ultraviolet light sources
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
352 participants (actual)

Study arms

  • Experimental
    Apremilast 10mg

    Apremilast 10 mg administered orally twice daily (BID) for 16 weeks (following dose titration) during the placebo controlled phase followed by 10 mg Apremilast tablets orally administered BID for 8 weeks in the active treatment phase

    Drug: Apremilast 10mg

  • Experimental
    Apremilast 20mg

    Apremilast 20 mg administered orally twice daily (BID) for 16 weeks (following dose titration) during the placebo controlled phase followed by 20 mg Apremilast tablets orally administered BID for 8 weeks in the active treatment phase

    Drug: Apremilast 20mg

  • Experimental
    Apremilast 30 mg

    Apremilast 30 mg administered orally twice daily (BID) for 16 weeks (following dose titration) during the placebo controlled phase followed by 30 mg Apremilast tablets orally administered BID for 8 weeks in the active treatment phase

    Drug: Apremilast 30 mg

  • Placebo comparator
    Placebo

    Oral Placebo tablets administered twice daily (BID) for 16 weeks during the placebo-controlled phase.

    Drug: Placebo

  • Experimental
    Placebo/Apremilast 20 mg

    Participants initially randomized to receive placebo twice daily during the 16 week placebo controlled phase are re-randomized to 20 mg apremilast BID during the 8 week active treatment phase

    Drug: Apremilast 20mg

  • Experimental
    Placebo/Apremilast 30mg

    Participants initially randomized to receive placebo twice daily during the 16 week placebo controlled phase are re-randomized to 30 mg apremilast BID during the 8 week active treatment phase

    Drug: Apremilast 30mg

Interventions

06

What researchers measure

Primary outcomes

  1. Core Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in Psoriasis Area and Severity Index (PASI) at Week 16

    PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 and Week 16

Secondary outcomes

  1. Core Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in PASI Score at Week 24

    PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 24. The improvement in PASI score was used as a measure of efficacy.The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head,trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 to Week 24

  2. Core Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in PASI Score at Week 16

    PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy The PASI score was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 to Week 16

  3. Core Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at Week 24

    PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 24. The improvement in PASI score was used as a measure of efficacy. The PASI score was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 to Week 24

  4. Core Study: Percentage of Participants Who Achieved a 90% Improvement (Response) From Baseline in the PASI Score at Week 16

    PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy. The PASI score was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 to Week 16

  5. Core Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at Week 24

    PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 24. The improvement in PASI score was used as a measure of efficacy..The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 to Week 24

  6. Core Study: Percentage of Participants Who Achieved a 100% Improvement (Response) in the PASI Score at Week 16

    A participant was classified as having achieved a PASI-100 response if the PASI score was reduced by at least 100% from baseline. The PASI score was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 to Week 16

  7. Core Study: Percentage of Participants Who Achieved a 100% Improvement (Response) in the PASI Score at Week 24

    A participant was classified as having achieved a PASI-100 response if the PASI score was reduced by at least 100% from baseline. The PASI score was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 to Week 24

  8. Core Study: Time to Achieve a PASI-100 Response During the Placebo Controlled Phase

    For PASI-100 responders in the placebo-controlled period weeks 0-16, time to achieve PASI-100 was the time interval, inclusive, between the date of randomization (day 1) and the date of the first assessment where PASI-90 was achieved.

    Time frame: Weeks 0 to 16

  9. Core Study: Percent Change From Baseline in PASI Score at Week 16

    The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score.

    Time frame: Week 0 to Week 16

  10. Core Study: Percent Change From Baseline in PASI Score at Week 24

    The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score

    Time frame: Week 0 to Week 24

  11. Core Study: Shift Change (1 or More Points on a 0 to 5 Point Scale) in Static Physician Global Assessment (sPGA) at Week 16

    Physician Global Assessment (sPGA) was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA is a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling. Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3).

    Time frame: Week 0 to Week 16

  12. Core Study: Shift Change (1 or More Points on a 0 to 5 Point Scale) in Static Physician Global Assessment (sPGA) at Week 24

    Physician Global Assessment (sPGA) was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA is a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling. Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3).

    Time frame: Week 0 to Week 24

  13. Core Study: Percent Change From Baseline in the Percent of Affected Body Surface Area (BSA) During the Placebo Controlled Phase

    The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.

    Time frame: Week 0 to Week 16

  14. Core Study: Percent Change From Baseline in the Percent of Affected Body Surface Area (BSA) During the Active Treatment Phase at Week 24

    The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.

    Time frame: Week 0 to Week 24

  15. Core Study: Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 16

    The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis.

    Time frame: Week 0 to Week 16

  16. Core Study: Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 24

    The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis.

    Time frame: Week 0 to Week 24

  17. Core Study: Change From Baseline in the Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2; Mental Component Summary Score at Week 16

    The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

    Time frame: Week 0 to Week 16

  18. Core Study: Change From Baseline in the Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2; Physical Component Summary Score at Week 16

    The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

    Time frame: Week 0 to week 16

  19. Core Study: Change From Baseline in the Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2; Mental Component Summary Score at Week 24

    The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

    Time frame: Week 0 to Week 24

  20. Core Study: Change From Baseline in the Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2 Physical Component Summary Score at Week 24

    The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

    Time frame: Week 0 to Week 24

  21. Core Study: Area Under the Plasma Concentration-time Curve (AUC0-8)

    Area under the concentration versus time curve from time 0 (pre-dose) to 8 hours, calculated using the linear trapezoid rule.

    Time frame: Week 14; Predose, 0.5, 1, 2, 3, 4, and 8 hours after the morning dose of apremilast

  22. Core Study: Area Under the Plasma Concentration-time Curve (AUC0-8)

    Area under the concentration versus time curve from time 0 (pre-dose) to 8 hours, calculate using the linear trapezoid rule.

    Time frame: Week 24

  23. Core Study: Peak; (Maximum) Plasma Concentration (Cmax) of Apremilast

    The maximum observed plasma concentration of apremilast observed at Week 14 (steady-state Cmax)

    Time frame: Week 14; Predose, 0.5, 1, 2, 3, 4, and 8 hours after the morning dose of apremilast

  24. Core Study: Peak; (Maximum) Plasma Concentration (Cmax) of Apremilast

    The maximum observed plasma concentration of apremilast observed at Week 24 (steady-state Cmax)

    Time frame: Week 24

  25. Core Study: Time to Maximum Plasma Concentration of Drug (Tmax)

    Time to achieve maximum plasma concentration (Cmax) observed at Week 14 (Time to achieve steady-state Tmax)

    Time frame: Week 14; Predose, 0.5, 1, 2, 3, 4, and 8 hours after the morning dose of apremilast

  26. Core Study: Time to Maximum Plasma Concentration of Drug (Tmax)

    Time to achieve maximum plasma concentration (tmax) observed at Week 24 (Time to achieve steady-state Tmax)

    Time frame: Week 24

  27. Extension Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at Week 52

    PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 52. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 to Week 52

  28. Extension Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at Week 32

    PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 32 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 to Week 32

  29. Extension Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at Week 40

    PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 40 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 to Week 40

  30. Extension Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at Week 32

    PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 32 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 to Week 32

  31. Extension Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at Week 40

    PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 16 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 to Week 40

  32. Extension Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at Week 52

    PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 52 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 to Week 52

  33. Extension Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at Week 32

    PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 32 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 to Week 32

  34. Extension Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at Week 40

    PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 40 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 to Week 40

  35. Extension Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at Week 52

    PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 52 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 to Week 52

  36. Extension Study: Percentage of Participants Who Achieved a 100% Improvement (Response) in the PASI Score at Week 32

    A participant was classified as having achieved a PASI-100 response if the PASI score was reduced by at least 100% from baseline. The PASI score was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 to Week 32

  37. Extension Study: Percentage of Participants Who Achieved a 100% Improvement (Response) in the PASI Score at Week 40

    A participant was classified as having achieved a PASI-100 response if the PASI score was reduced by at least 100% from baseline. The PASI score was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 to Week 40

  38. Extension Study: Percentage of Participants Who Achieved a 100% Improvement (Response) in the PASI Score at Week 52

    A participant was classified as having achieved a PASI-100 response if the PASI score was reduced by at least 100% from baseline. The PASI score was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 to Week 52

  39. Extension Study: Time to Achieve PASI-75 During the Extension Study

    For PASI-75 responders in the extension study, time to achieve PASI-75 was defined as the time interval, inclusive between the date of randomization (Day 1) and the date of the first assessment where PASI-75 was achieved.

    Time frame: Week 0 to Week 52

  40. Extension Study: Time to Achieve PASI-50 During the Extension Study

    For PASI-50 responders in the extension study, time to achieve PASI-50 was defined as the time interval, inclusive between the date of randomization (Day 1) and the date of the first assessment where PASI-50 was achieved.

    Time frame: Week 0 to Week 52

  41. Extension Study: Time to Achieve PASI-90 During the Extension Study

    For PASI-90 responders in the extension study, time to achieve PASI-90 was defined as the time interval, inclusive between the date of randomization (Day 1) and the date of the first assessment where PASI-90 was achieved.

    Time frame: Week 0 to Extension study

  42. Extension Study: Time to Achieve PASI-100 During the Extension Study

    For PASI-100 responders in the extension study, time to achieve PASI-100 was defined as the time interval, inclusive between the date of randomization (Day 1) and the date of the first assessment where PASI-100 was achieved.

    Time frame: Week 0 to Extension Study

  43. Extension Study: Percent Change in PASI Score at Week 32

    The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score

    Time frame: Week 0 to Week 32

  44. Extension Study: Percent Change in PASI Score at Week 40

    The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score

    Time frame: Week 0 to Week 40

  45. Extension Study: Percent Change in PASI Score at Week 52

    The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score

    Time frame: Week 0 to Week 52

  46. Extension Study: Shift Change (1 or More Points on a 0 to 5 Point Scale) in Static Physician Global Assessment (sPGA) at Week 32

    Physician Global Assessment (sPGA) was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA is a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the subject and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling. Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3).

    Time frame: Week 0 to Week 32

  47. Extension Study: Shift Change (1 or More Points on a 0 to 5 Point Scale) in Static Physician Global Assessment (sPGA) at Week 40

    Physician Global Assessment (sPGA) was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA is a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the subject and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling. Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3).

    Time frame: Week 0 to Week 40

  48. Extension Study: Shift Change (1 or More Points on a 0 to 5 Point Scale) in Static Physician Global Assessment (sPGA) at Week 52

    Physician Global Assessment (sPGA) was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA is a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the subject and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling. Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3).

    Time frame: Week 0 to Week 52

  49. Extension Study: Percent Change From Baseline in the Affected BSA at Week 32

    The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.

    Time frame: Week 0 to Week 32

  50. Extension Study: Percent Change From Baseline in the Affected BSA at Week 40

    The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.

    Time frame: Week 0 to Week 40

  51. Extension Study: Percent Change From Baseline in the Affected BSA at Week 52

    The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.

    Time frame: Week 0 to Week 52

  52. Extension Study: Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 32

    The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis.

    Time frame: Week 0 to Week 32

  53. Extension Study: Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 40

    The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis.

    Time frame: Week 0 to Week 40

  54. Extension Study: Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 52

    The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis.

    Time frame: Week 0 to Week 52

  55. Extension Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Mental Component Summary Score at Week 32

    The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

    Time frame: Week 0 to Week 32

  56. Extension Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Physical Component Summary Score (PCS) at Week 32

    The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

    Time frame: Week 0 to Week 32

  57. Extension Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Mental Component Summary Score at Week 40

    The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

    Time frame: Week 0 to Week 40

  58. Extension Study: Change From Baseline in Medical Outcome Study Short Form,SF-36, Version 2; Physical Component Summary Score at Week 40

    The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

    Time frame: Week 0 to Week 40

  59. Extension Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Mental Component Summary Score at Week 52

    The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

    Time frame: Week 0 to Week 52

  60. Extension Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Physical Component Summary Score at Week 52

    The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value..

    Time frame: Week 0 to Week 52

  61. Extension Study: Dose-response Relationship Using the Percent Reduction of PASI Scores at Week 52

    Dose response relationship using percent reduction in PASI scores across dose groups at Week 52 compared to Week 0

    Time frame: Week 0 to Week 52

  62. Extension Study: Time to Loss of Response During the Treatment Phase of the Extension Study.

    Time to 50% loss of the maximal improvement (achieved in either the core study or the extension study) during the treatment phase of the extension study, in participants who achieved ≥ PASI-50 in either the core study or during the treatment phase of the extension study

    Time frame: Week 0 to 52

  63. Time to Loss of 50% of the PASI Response During the Observational Follow-up Phase Relative to the End of Treatment (Participants Who Had at Least a PASI-50 Response at the End of Treatment Phase)

    Time to loss of response was modified to be 50% loss in the PASI response observed at the end of treatment for participants who achieved at least a PASI-50 at the end of treatment. This definition was changed since participants may have already lost their maximal PASI response prior to enrollment into the Observation Follow-up Phase. Included all participants that enrolled into the observational follow-up phase after the treatment phase.

    Time frame: Up to 4 weeks after the last dose

  64. Number of Participants With Treatment Emergent Adverse Events (TEAE) in the Placebo Controlled Phase

    An AE was any noxious, unintended, or untoward medical occurrence, that may appear or worsen in a participant during the course of study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above. An AE is a treatment emergent AE if the AE start date is on or after the date of the first dose of study drug and no later than 28 days after the last dose.

    Time frame: Week 0 to Week 16; up to data cut off of 21 July 2011

  65. Number of Participants With Treatment Emergent Adverse Events (TEAE) in the Apremilast Exposure Period

    An AE was any noxious, unintended, or untoward medical occurrence, that may appear or worsen in a participant during the course of study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above. An AE is a treatment emergent AE if the AE start date is on or after the date of the first dose of study drug and no later than 28 days after the last dose.

    Time frame: Week 0-88; up to data cut off of 21 July 2011

  66. Core Study: Time to Achieve a PASI-50 Response During the Placebo Controlled Phase

    For PASI-50 responders in the placebo-controlled period weeks 0-16, time to achieve PASI-50 was defined as the time interval, inclusive between the date of randomization (day 1) and the date of the first assessment where PASI-50 was achieved.

    Time frame: Week 0 to 16

  67. Core Study: Time to Achieve a PASI-75 Response During the Placebo Controlled Phase

    For PASI-75 responders in the placebo-controlled period Weeks 0-16, time to achieve PASI-75 was defined as the time interval, inclusive between the date of randomization (day 1) and the date of the first assessment where PASI-75 is achieved.

    Time frame: Weeks 0 to 16

  68. Core Study: Time to Achieve a PASI-90 Response During the Placebo Controlled Phase

    For PASI-90 responders in the placebo-controlled period weeks 0-16, time to achieve PASI-90 was the time interval, inclusive, between the date of randomization (day 1) and the date of the first assessment where PASI-90 was achieved.

    Time frame: Weeks 0 to 16

  69. Number of Participants With Treatment Emergent Adverse Events (TEAE) in the Apremilast Exposure Period

    An AE was any noxious, unintended, or untoward medical occurrence, that may appear or worsen in a participant during the course of study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above. An AE is a treatment emergent AE if the AE start date is on or after the date of the first dose of study drug and no later than 28 days after the last dose.

    Time frame: Week 0 to 6 years of study treatment; maximum duration of exposure was 314.6 weeks

  70. LTE Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at 18 Months

    PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 to Month 18

  71. LTE Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at 2 Years

    PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 to Month 24

  72. LTE Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at 3 Years

    PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 to Month 36

  73. LTE Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at 4 Years

    PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 to Month 48

  74. LTE Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at 18 Months

    PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 to Month 18

  75. LTE Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at 2 Years

    PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 to Month 24

  76. LTE Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at 3 Years

    PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 to Month 36

  77. LTE Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at 4 Years

    PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 to Month 48

  78. LTE Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at 18 Months

    PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 76 of the long-term extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 to Month 18

  79. LTE Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at 2 Years

    PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 100 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 to Month 24

  80. LTE Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at 3 Years

    PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 148 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 to Month 36

  81. LTE Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at 4 Years

    PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 196 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 to Month 48

  82. LTE Study: Percentage of Participants Who Achieved a 100% Improvement (Response) in the PASI Score at 18 Months, 2 Years, 3 Years and 4 Years

    PASI-100 response is the percentage of participants who achieved at a 100% reduction (improvement) from baseline in PASI score of the long-term extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

    Time frame: Week 0 to Month 48

  83. LTE Study: Percent Change From Baseline in PASI Score at 18 Months

    The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score

    Time frame: Week 0 to Month 18

  84. LTE Study: Percent Change From Baseline in PASI Score at 2 Years

    The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score

    Time frame: Week 0 to Month 24

  85. LTE Study: Percent Change From Baseline in PASI Score at 3 Years

    The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score

    Time frame: Week 0 to Month 36

  86. LTE Study: Percent Change From Baseline in PASI Score at 4 Years

    The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score

    Time frame: Week 0 to Month 48

  87. Core Study: Shift Change (1 or More Points on a 0 to 5 Point Scale) in Static Physician Global Assessment (sPGA) at Month 18, and Years 2, 3 and 4

    Physician Global Assessment (sPGA) was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA is a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling. Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3).

    Time frame: Week 0 to Week 196

  88. LTE Study: Percent Change From Baseline in the Percent of the Affected Body Surface Area (BSA) at 18 Months

    The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.

    Time frame: Week 0 to Month 18

  89. LTE Study: Percent Change From Baseline in the Percent of the Affected Body Surface Area (BSA) at 2 Years

    The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.

    Time frame: Week 0 to Month 24

  90. LTE Study: Percent Change From Baseline in the Percent of the Affected Body Surface Area (BSA) at 3 Years

    The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.

    Time frame: Week 0 to Month 36

  91. LTE Study: Percent Change From Baseline in the Percent of the Affected Body Surface Area (BSA) at 4 Years

    The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.

    Time frame: Week 0 to Month 48

  92. LTE Study: Median Percent Change From Baseline in the Affected Body Surface Area (BSA) at 18 Months

    The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.

    Time frame: Week 0 to Month 18

  93. LTE Study: Median Percent Change From Baseline in the Affected Body Surface Area (BSA) at 2 Years

    The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.

    Time frame: Week 0 to Month 24

  94. LTE Study: Median Percent Change From Baseline in the Affected Body Surface Area (BSA) at 3 Years

    The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.

    Time frame: Week 0 to Month 36

  95. LTE Study: Median Percent Change From Baseline in the Affected Body Surface Area (BSA) at 4 Years

    The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.

    Time frame: Week 0 to Month 48

  96. LTE Study: Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at 18 Months

    The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis.

    Time frame: Week 0 to Month 18

  97. LTE Study: Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at 2 Years

    The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis.

    Time frame: Week 0 to Month 24

  98. LTE Study: Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at 3 Years

    The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis.

    Time frame: Week 0 to Month 36

  99. LTE Study: Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at 4 Years

    The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis.

    Time frame: Week 0 to Month 48

  100. LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Mental Component Summary Score at 18 Months

    The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

    Time frame: Week 0 to Month 18

  101. LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Mental Component Summary Score at 2 Years

    The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

    Time frame: Week 0 to Month 24

  102. LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Mental Component Summary Score at 3 Years

    The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

    Time frame: Week 0 to Month 36

  103. LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Mental Component Summary Score at 4 Years

    The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

    Time frame: Week 0 to Month 48

  104. LTE Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Physical Component Summary Score at 18 Months

    The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

    Time frame: Week 0 to Month 18

  105. LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Physical Component Summary Score at 2 Years

    The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

    Time frame: Week 0 to Month 24

  106. LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Physical Component Summary Score at 3 Years

    The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

    Time frame: Week 0 to Month 36

  107. LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Physical Component Summary Score at 4 Years

    The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

    Time frame: Week 0 to Month 48

Other outcomes

  1. Core Study: Percentage of Participants With a Static Physician Global Assessment (sPGA) Greater Than 2 at Baseline Who Achieved a Score of 0 or 1 at Week 16

    The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less severe disease

    Time frame: Week 0 to Week 16

  2. Core Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at Week 24

    The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less severe disease

    Time frame: Week 0 and Week 24

  3. Extension Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at Week 32

    The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less severe disease.

    Time frame: Week 0 to Week 32

  4. Extension Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at Week 40

    The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less disease.

    Time frame: Week 0 to Week 40

  5. Extension Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at Week 52

    The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less severe disease.

    Time frame: Week 0 to Week 52

  6. LTE Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at 18 Months

    The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less severe disease

    Time frame: Week 0 to Month 18

  7. LTE Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at 2 Years

    The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less severe disease

    Time frame: Week 0 to Month 24

  8. LTE Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at 3 Years

    The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less severe disease

    Time frame: Week 0 and month 36

  9. LTE Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at 4 Years

    The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less severe disease

    Time frame: Week 0 to Month 48

07

Results

Posted Nov 13, 2014

Participant flow

The study consisted of a 16-week randomized, double-blind, placebo-controlled phase, and a 8-week active treatment phase. At Week 24, subjects may have continued on active treatment by entering a 28-week extension study, total = 52 weeks; At completion of the extension study, subjects may have entered in a long term extension (LTE) for 5 + years.

Core: Placebo Controlled Phase Week 0-16
Participant flow — Core: Placebo Controlled Phase Week 0-16
MilestonePlaceboApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Started8889878800
Completed7279667000
Not completed1610211800
Withdrew: Adverse event5181000
Withdrew: Lack of efficacy432200
Withdrew: Withdrawal by subject226400
Withdrew: Death100000
Withdrew: Lost to follow-up200100
Withdrew: Protocol violation134000
Withdrew: Other111100
Core: Active Treatment Phase Week 16-24
Participant flow — Core: Active Treatment Phase Week 16-24
MilestonePlaceboApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Started07766673436
Completed06559653331
Not completed0127215
Withdrew: Adverse event040012
Withdrew: Lack of efficacy044100
Withdrew: Withdrawal by subject011002
Withdrew: Lost to follow-up011000
Withdrew: Protocol violation011101
Withdrew: Other010000
Extension: Active Treatment Week 24-52
Participant flow — Extension: Active Treatment Week 24-52
MilestonePlaceboApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Started04750582727
Completed extension and continued lte05101044
Completed03433482219
Not completed013171058
Withdrew: Adverse event000021
Withdrew: Lack of efficacy0810312
Withdrew: Withdrawal by subject031223
Withdrew: Lost to follow-up025301
Withdrew: Other001201
LTE Period: Week 52 to 6 Years
Participant flow — LTE Period: Week 52 to 6 Years
MilestonePlaceboApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Started00161700
Completed004500
Not completed00121200
Withdrew: Adverse event000100
Withdrew: Lack of efficacy002400
Withdrew: Withdrawal by subject006300
Withdrew: Lost to follow-up004400

Outcome measures

PrimaryCore Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in Psoriasis Area and Severity Index (PASI) at Week 16

PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 and Week 16
Reported as:
Number · percentage of participants
Core Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in Psoriasis Area and Severity Index (PASI) at Week 16
percentage of participantsPlacebo BIDApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BID
Core Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in Psoriasis Area and Severity Index (PASI) at Week 165.711.228.740.9
Statistical analysis
  • Placebo BID vs Apremilast 10mg BID · Chi-squared · p = 0.1846 · Risk difference (rd): 5.6 · 95% CI -2.6 to 13.7
  • Placebo BID vs Apremilast 20mg BID · Chi-squared · p = <0.0001 · Risk difference (rd): 23.1 · 95% CI 12.4 to 33.7
  • Placebo BID vs Apremilast 30 mg BID · Chi-squared · p = <0.0001 · Risk difference (rd): 35.2 · 95% CI 23.9 to 46.6
SecondaryCore Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in PASI Score at Week 24

PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 24. The improvement in PASI score was used as a measure of efficacy.The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head,trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 to Week 24
Reported as:
Number · percentage of participants
Core Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in PASI Score at Week 24
percentage of participantsApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPBO-Apremilast 20mg BIDPBO-Apremilast 30 mg BID
Core Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in PASI Score at Week 2418.0 (10.6 to 27.5)26.4 (17.6 to 37.0)39.8 (29.5 to 50.8)41.2 (24.6 to 59.3)44.4 (27.9 to 61.9)
SecondaryCore Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in PASI Score at Week 16

PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy The PASI score was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 to Week 16
Reported as:
Number · percentage of participants
Core Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in PASI Score at Week 16
percentage of participantsPlacebo BIDApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BID
Core Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in PASI Score at Week 1625.038.247.160.2
Statistical analysis
  • Placebo BID vs Apremilast 10mg BID · Chi-squared · p = 0.0590 · Risk difference (rd): 13.2 · 95% CI -0.4 to 26.8
  • Placebo BID vs Apremilast 20mg BID · Chi-squared · p = 0.0023 · Risk difference (rd): 22.1 · 95% CI 8.3 to 36.0
  • Placebo BID vs Apremilast 30 mg BID · Chi-squared · p = <0.0001 · Risk difference (rd): 35.2 · 95% CI 21.6 to 48.9
SecondaryCore Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at Week 24

PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 24. The improvement in PASI score was used as a measure of efficacy. The PASI score was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 to Week 24
Reported as:
Number · percentage of participants
Core Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at Week 24
percentage of participantsApremilast 10mg BIDApremilast 20mgApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPBO-Apremilast 30 mg BID
Core Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at Week 2438.2 (28.1 to 49.1)49.4 (38.5 to 60.4)65.9 (55.0 to 75.7)61.8 (43.6 to 77.8)75.0 (57.8 to 87.9)
SecondaryCore Study: Percentage of Participants Who Achieved a 90% Improvement (Response) From Baseline in the PASI Score at Week 16

PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy. The PASI score was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 to Week 16
Reported as:
Number · percentage of participants
Core Study: Percentage of Participants Who Achieved a 90% Improvement (Response) From Baseline in the PASI Score at Week 16
percentage of participantsPlacebo BIDApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BID
Core Study: Percentage of Participants Who Achieved a 90% Improvement (Response) From Baseline in the PASI Score at Week 161.14.59.211.4
Statistical analysis
  • Placebo BID vs Apremilast 10mg BID · Chi-squared · p = 0.1776 · Risk difference (rd): 3.4 · 95% CI -1.5 to 8.2
  • Placebo BID vs Apremilast 20mg BID · Chi-squared · p = 0.0158 · Risk difference (rd): 8.1 · 95% CI 1.6 to 14.5
  • Placebo BID vs Apremilast 30 mg BID · Chi-squared · p = 0.0051 · Risk difference (rd): 10.2 · 95% CI 3.2 to 17.2
SecondaryCore Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at Week 24

PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 24. The improvement in PASI score was used as a measure of efficacy..The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 to Week 24
Reported as:
Number · percentage of participants
Core Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at Week 24
percentage of participantsApremilast 10mgApremilast 20mgApremilast 30 mgPBO-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Core Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at Week 244.5 (1.2 to 11.1)8.0 (3.3 to 15.9)14.8 (8.1 to 23.9)14.7 (5.0 to 31.1)16.7 (6.4 to 32.8)
SecondaryCore Study: Percentage of Participants Who Achieved a 100% Improvement (Response) in the PASI Score at Week 16

A participant was classified as having achieved a PASI-100 response if the PASI score was reduced by at least 100% from baseline. The PASI score was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 to Week 16

No measurements were reported for this outcome.

SecondaryCore Study: Percentage of Participants Who Achieved a 100% Improvement (Response) in the PASI Score at Week 24

A participant was classified as having achieved a PASI-100 response if the PASI score was reduced by at least 100% from baseline. The PASI score was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 to Week 24

No measurements were reported for this outcome.

SecondaryCore Study: Time to Achieve a PASI-100 Response During the Placebo Controlled Phase

For PASI-100 responders in the placebo-controlled period weeks 0-16, time to achieve PASI-100 was the time interval, inclusive, between the date of randomization (day 1) and the date of the first assessment where PASI-90 was achieved.

Time frame:
Weeks 0 to 16

No measurements were reported for this outcome.

SecondaryCore Study: Percent Change From Baseline in PASI Score at Week 16

The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score.

Time frame:
Week 0 to Week 16
Reported as:
Least squares mean · Percent change
Core Study: Percent Change From Baseline in PASI Score at Week 16
Percent changePlacebo BIDApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BID
Core Study: Percent Change From Baseline in PASI Score at Week 16-20.3 ± 3.98-34.0 ± 4.00-45.4 ± 4.12-53.2 ± 4.00
Statistical analysis
  • Placebo BID vs Apremilast 10mg BID · ANCOVA · p = 0.0156 · Least square mean difference: -13.7 · 95% CI -24.8 to -2.6Analysis of covariance model with treatment group as a factor and the baseline value as a covariate.
  • Placebo BID vs Apremilast 20mg BID · ANCOVA · p = <0.0001 · Ls mean difference: -25.1 · 95% CI -36.4 to -13.9Analysis of covariance model with treatment group as a factor and the baseline value as a covariate.
  • Placebo BID vs Apremilast 30 mg BID · ANCOVA · p = <0.0001 · Ls mean difference: -32.9 · 95% CI -44.0 to -21.7Analysis of covariance model with treatment group as a factor and the baseline value as a covariate.
SecondaryCore Study: Percent Change From Baseline in PASI Score at Week 24

The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score

Time frame:
Week 0 to Week 24
Reported as:
Mean · percent change
Core Study: Percent Change From Baseline in PASI Score at Week 24
percent changeApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPBO-Apremilast 20mg BIDPBO-Apremilast 30 mg BID
Core Study: Percent Change From Baseline in PASI Score at Week 24-36.3 ± 36.03-46.5 ± 36.08-56.8 ± 34.99-61.7 ± 25.35-61.7 ± 32.67
Other pre-specifiedCore Study: Percentage of Participants With a Static Physician Global Assessment (sPGA) Greater Than 2 at Baseline Who Achieved a Score of 0 or 1 at Week 16

The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less severe disease

Time frame:
Week 0 to Week 16
Reported as:
Number · percentage of participants
Core Study: Percentage of Participants With a Static Physician Global Assessment (sPGA) Greater Than 2 at Baseline Who Achieved a Score of 0 or 1 at Week 16
percentage of participantsPlaceboApremilast 10mgApremilast 20mgApremilast 30 mg
Core Study: Percentage of Participants With a Static Physician Global Assessment (sPGA) Greater Than 2 at Baseline Who Achieved a Score of 0 or 1 at Week 1612.610.525.033.7
Statistical analysis
  • Placebo vs Apremilast 10mg · Chi-squared · p = 0.6541 · Risk difference (rd): -2.2 · 95% CI -11.7 to 7.3
  • Placebo vs Apremilast 20mg · Chi-squared · p = 0.0402 · Risk difference (rd): 12.4 · 95% CI 0.6 to 24.1
  • Placebo vs Apremilast 30 mg · Chi-squared · p = 0.0011 · Risk difference (rd): 21.1 · 95% CI 8.8 to 33.4
Other pre-specifiedCore Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at Week 24

The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less severe disease

Time frame:
Week 0 and Week 24
Reported as:
Number · percentage of participants
Core Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at Week 24
percentage of participantsApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20 mg BIDPlacebo-Apremilast 30 mg BID
Core Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at Week 2413.5 (7.2 to 22.4)24.1 (15.6 to 34.5)34.1 (24.3 to 45.0)41.2 (24.6 to 59.3)50.0 (32.9 to 67.1)
SecondaryCore Study: Shift Change (1 or More Points on a 0 to 5 Point Scale) in Static Physician Global Assessment (sPGA) at Week 16

Physician Global Assessment (sPGA) was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA is a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling. Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3).

Time frame:
Week 0 to Week 16

No measurements were reported for this outcome.

SecondaryCore Study: Shift Change (1 or More Points on a 0 to 5 Point Scale) in Static Physician Global Assessment (sPGA) at Week 24

Physician Global Assessment (sPGA) was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA is a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling. Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3).

Time frame:
Week 0 to Week 24

No measurements were reported for this outcome.

SecondaryCore Study: Percent Change From Baseline in the Percent of Affected Body Surface Area (BSA) During the Placebo Controlled Phase

The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.

Time frame:
Week 0 to Week 16
Reported as:
Least squares mean · percent change
Core Study: Percent Change From Baseline in the Percent of Affected Body Surface Area (BSA) During the Placebo Controlled Phase
percent changePlacebo BIDApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BID
Core Study: Percent Change From Baseline in the Percent of Affected Body Surface Area (BSA) During the Placebo Controlled Phase-8.0 ± 4.58-28.3 ± 4.60-38.0 ± 4.74-50.4 ± 4.63
Statistical analysis
  • Placebo BID vs Apremilast 10mg BID · ANCOVA · p = 0.0020 · Ls mean difference: -20.2 · 95% CI -33.0 to -7.5Based on an analysis of covariance model with treatment group as a factor and the baseline value as a covariate
  • Placebo BID vs Apremilast 20mg BID · ANCOVA · p = <0.0001 · Ls mean difference: -29.9 · 95% CI -42.9 to -17.0based on an analysis of covariance model with treatment group as a factor and the baseline value as a covariate
  • Placebo BID vs Apremilast 30 mg BID · ANCOVA · p = <0.0001 (Based on an analysis of covariance model with treatment group as a factor and the baseline value as a covariate) · Ls mean difference: -42.4 · 95% CI -55.2 to -29.5
SecondaryCore Study: Percent Change From Baseline in the Percent of Affected Body Surface Area (BSA) During the Active Treatment Phase at Week 24

The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.

Time frame:
Week 0 to Week 24
Reported as:
Mean · percent change
Core Study: Percent Change From Baseline in the Percent of Affected Body Surface Area (BSA) During the Active Treatment Phase at Week 24
percent changeApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20 mg BIDPlacebo-Apremilast 30 mg BID
Core Study: Percent Change From Baseline in the Percent of Affected Body Surface Area (BSA) During the Active Treatment Phase at Week 24-28.1 ± 46.78-40.6 ± 43.71-54.0 ± 37.32-52.5 ± 37.35-54.2 ± 42.08
SecondaryCore Study: Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 16

The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis.

Time frame:
Week 0 to Week 16
Reported as:
Least squares mean · units on a scale
Core Study: Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 16
units on a scalePlacebo BIDApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BID
Core Study: Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 16-1.9 ± 0.63-3.2 ± 0.62-5.9 ± 0.65-4.4 ± 0.63
Statistical analysis
  • Placebo BID vs Apremilast 10mg BID · ANCOVA · p = 0.1322 · Difference in ls means: -1.3 · 95% CI -3.1 to 0.4Based on an analysis of covariance model with treatment group as a factor and the baseline value as a covariate.
  • Placebo BID vs Apremilast 20mg BID · ANCOVA · p = <0.0001 · Difference in ls means: -4.1 · 95% CI -5.9 to -2.3Based on an analysis of covariance model with treatment group as a factor and the baseline value as a covariate.
  • Placebo BID vs Apremilast 30 mg BID · ANCOVA · p = 0.0047 · Difference in ls means: -2.6 · 95% CI -4.3 to -0.8Based on an analysis of covariance model with treatment group as a factor and the baseline value as a covariate.
SecondaryCore Study: Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 24

The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis.

Time frame:
Week 0 to Week 24
Reported as:
Mean · units on a scale
Core Study: Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 24
units on a scaleApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast (APR) 20 mg BIDPlacebo-Apremilast 30 mg BID
Core Study: Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 24-3.4 ± 6.40-6.2 ± 6.53-4.9 ± 5.18-6.4 ± 6.64-5.4 ± 5.32
SecondaryCore Study: Change From Baseline in the Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2; Mental Component Summary Score at Week 16

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

Time frame:
Week 0 to Week 16
Reported as:
Least squares mean · units on a scale
Core Study: Change From Baseline in the Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2; Mental Component Summary Score at Week 16
units on a scalePlacebo BIDApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BID
Core Study: Change From Baseline in the Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2; Mental Component Summary Score at Week 16-0.6 ± 0.892.8 ± 0.872.9 ± 0.923.0 ± 0.89
Statistical analysis
  • Placebo BID vs Apremilast 10mg BID · ANCOVA · p = 0.0078 · Difference in ls means: 3.3 · 95% CI 0.9 to 5.8Based on an analysis of covariance model with treatment group as a factor and the baseline value as a covariate.
  • Placebo BID vs Apremilast 20mg BID · ANCOVA · p = 0.0068 · Difference in ls means: 3.5 · 95% CI 1.0 to 6.0Based on an analysis of covariance model with treatment group as a factor and the baseline value as a covariate.
  • Placebo BID vs Apremilast 30 mg BID · ANCOVA · p = 0.0045 · Difference in ls means: 3.6 · 95% CI 1.1 to 6.1Based on an analysis of covariance model with treatment group as a factor and the baseline value as a covariate.
SecondaryCore Study: Change From Baseline in the Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2; Physical Component Summary Score at Week 16

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

Time frame:
Week 0 to week 16
Reported as:
Least squares mean · units on a scale
Core Study: Change From Baseline in the Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2; Physical Component Summary Score at Week 16
units on a scalePlacebo BIDApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BID
Core Study: Change From Baseline in the Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2; Physical Component Summary Score at Week 160.7 ± 0.801.3 ± 0.782.1 ± 0.830.8 ± 0.80
Statistical analysis
  • Placebo BID vs Apremilast 10mg BID · ANCOVA · p = 0.6097 · Difference in ls means: 0.6 · 95% CI -1.6 to 2.8Based on an analysis of covariance model with treatment group as a factor and the baseline value as a covariate.
  • Placebo BID vs Apremilast 20mg BID · ANCOVA · p = 0.2424 · Difference in ls means: 1.3 · 95% CI -0.9 to 3.6Based on an analysis of covariance model with treatment group as a factor and the baseline value as a covariate.
  • Placebo BID vs Apremilast 30 mg BID · ANCOVA · p = 0.9528 · Difference in ls means: 0.1 · 95% CI -2.2 to 2.3Based on an analysis of covariance model with treatment group as a factor and the baseline value as a covariate.
SecondaryCore Study: Change From Baseline in the Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2; Mental Component Summary Score at Week 24

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

Time frame:
Week 0 to Week 24
Reported as:
Mean · units on a scale
Core Study: Change From Baseline in the Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2; Mental Component Summary Score at Week 24
units on a scaleApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPBO-Apremilast 20mg BIDPBO-Apremilast 30 mg BID
Core Study: Change From Baseline in the Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2; Mental Component Summary Score at Week 242.8 ± 9.163.9 ± 9.562.9 ± 10.222.8 ± 10.960.5 ± 9.17
SecondaryCore Study: Change From Baseline in the Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2 Physical Component Summary Score at Week 24

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

Time frame:
Week 0 to Week 24
Reported as:
Mean · units on a scale
Core Study: Change From Baseline in the Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2 Physical Component Summary Score at Week 24
units on a scaleApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPBO-Apremilast 20mg BIDPBO-Apremilast 30 mg BID
Core Study: Change From Baseline in the Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2 Physical Component Summary Score at Week 241.1 ± 6.422.3 ± 8.291.0 ± 7.722.5 ± 9.342.7 ± 8.24
SecondaryCore Study: Area Under the Plasma Concentration-time Curve (AUC0-8)

Area under the concentration versus time curve from time 0 (pre-dose) to 8 hours, calculated using the linear trapezoid rule.

Time frame:
Week 14; Predose, 0.5, 1, 2, 3, 4, and 8 hours after the morning dose of apremilast
Reported as:
Geometric mean · ng*h/mL
Core Study: Area Under the Plasma Concentration-time Curve (AUC0-8)
ng*h/mLApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BID
Core Study: Area Under the Plasma Concentration-time Curve (AUC0-8)1008 ± 35.81591 ± 56.93467 ± 20.8
SecondaryCore Study: Area Under the Plasma Concentration-time Curve (AUC0-8)

Area under the concentration versus time curve from time 0 (pre-dose) to 8 hours, calculate using the linear trapezoid rule.

Time frame:
Week 24
Reported as:
Geometric mean · ng*h/mL
Core Study: Area Under the Plasma Concentration-time Curve (AUC0-8)
ng*h/mLApremilast 10mgApremilast 20mgApremilast 30 mg
Core Study: Area Under the Plasma Concentration-time Curve (AUC0-8)1200 ± 44.61257 ± 47.13477 ± 29.3
SecondaryCore Study: Peak; (Maximum) Plasma Concentration (Cmax) of Apremilast

The maximum observed plasma concentration of apremilast observed at Week 14 (steady-state Cmax)

Time frame:
Week 14; Predose, 0.5, 1, 2, 3, 4, and 8 hours after the morning dose of apremilast
Reported as:
Geometric mean · ng/mL
Core Study: Peak; (Maximum) Plasma Concentration (Cmax) of Apremilast
ng/mLApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BID
Core Study: Peak; (Maximum) Plasma Concentration (Cmax) of Apremilast209 ± 27.9298 ± 48.3637 ± 18.7
SecondaryCore Study: Peak; (Maximum) Plasma Concentration (Cmax) of Apremilast

The maximum observed plasma concentration of apremilast observed at Week 24 (steady-state Cmax)

Time frame:
Week 24
Reported as:
Geometric mean · ng/mL
Core Study: Peak; (Maximum) Plasma Concentration (Cmax) of Apremilast
ng/mLApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BID
Core Study: Peak; (Maximum) Plasma Concentration (Cmax) of Apremilast238 ± 45.2236 ± 39.7670 ± 20.4
SecondaryCore Study: Time to Maximum Plasma Concentration of Drug (Tmax)

Time to achieve maximum plasma concentration (Cmax) observed at Week 14 (Time to achieve steady-state Tmax)

Time frame:
Week 14; Predose, 0.5, 1, 2, 3, 4, and 8 hours after the morning dose of apremilast
Reported as:
Median · hours
Core Study: Time to Maximum Plasma Concentration of Drug (Tmax)
hoursApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BID
Core Study: Time to Maximum Plasma Concentration of Drug (Tmax)2.00 (1.00 to 4.00)2.00 (1.00 to 4.00)1.00 (1.00 to 2.00)
SecondaryCore Study: Time to Maximum Plasma Concentration of Drug (Tmax)

Time to achieve maximum plasma concentration (tmax) observed at Week 24 (Time to achieve steady-state Tmax)

Time frame:
Week 24
Reported as:
Median · hours
Core Study: Time to Maximum Plasma Concentration of Drug (Tmax)
hoursApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BID
Core Study: Time to Maximum Plasma Concentration of Drug (Tmax)1.00 (1.00 to 3.00)1.50 (1.00 to 4.00)1.00 (0.500 to 1.00)
SecondaryExtension Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at Week 52

PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 52. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 to Week 52
Reported as:
Number · percentage of participants
Extension Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at Week 52
percentage of participantsApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Extension Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at Week 5214.9 (6.2 to 28.3)22.0 (11.5 to 36.0)36.2 (24.0 to 49.0)37.0 (19.4 to 57.6)33.3 (16.5 to 54.0)
SecondaryExtension Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at Week 32

PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 32 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 to Week 32
Reported as:
Number · percentage of participants
Extension Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at Week 32
percentage of participantsApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Extension Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at Week 3227.7 (15.6 to 42.6)38.0 (24.7 to 52.8)46.6 (33.3 to 60.1)33.3 (16.5 to 54.0)55.6 (35.3 to 74.5)
SecondaryExtension Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at Week 40

PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 40 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 to Week 40
Reported as:
Number · percentage of participants
Extension Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at Week 40
percentage of participantsApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Extension Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at Week 4021.3 (10.7 to 35.7)28.0 (16.2 to 42.5)34.5 (22.5 to 48.1)37.0 (19.4 to 57.6)44.4 (25.5 to 64.7)
SecondaryExtension Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at Week 32

PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 32 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 to Week 32
Reported as:
Number · percentage of participants
Extension Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at Week 32
percentage of participantsApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Extension Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at Week 3257.4 (42.2 to 71.7)72.0 (57.5 to 83.8)86.2 (74.6 to 93.9)74.1 (53.7 to 88.9)74.1 (53.7 to 88.9)
SecondaryExtension Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at Week 40

PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 16 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 to Week 40
Reported as:
Number · percentage of participants
Extension Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at Week 40
percentage of participantsApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Extension Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at Week 4048.9 (34.1 to 63.9)62.0 (47.2 to 75.3)82.8 (70.6 to 91.4)63.0 (42.4 to 80.6)66.7 (46.0 to 83.5)
SecondaryExtension Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at Week 52

PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 52 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 to Week 52
Reported as:
Number · percentage of participants
Extension Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at Week 52
percentage of participantsApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Extension Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at Week 5242.6 (28.3 to 57.8)48.0 (33.7 to 62.6)72.4 (59.1 to 83.6)55.6 (35.3 to 74.5)48.1 (28.7 to 68.1)
SecondaryExtension Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at Week 32

PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 32 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 to Week 32
Reported as:
Number · percentage of participants
Extension Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at Week 32
percentage of participantsApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Extension Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at Week 3210.6 (3.5 to 23.1)14.0 (5.8 to 26.7)19.0 (9.9 to 31.4)18.5 (6.3 to 38.1)25.9 (11.1 to 46.3)
SecondaryExtension Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at Week 40

PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 40 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 to Week 40
Reported as:
Number · percentage of participants
Extension Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at Week 40
percentage of participantsApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Extension Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at Week 408.5 (2.4 to 20.4)14.0 (5.8 to 26.7)17.2 (8.6 to 29.4)18.5 (6.3 to 38.1)22.2 (8.6 to 42.3)
SecondaryExtension Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at Week 52

PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 52 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 to Week 52
Reported as:
Number · percentage of participants
Extension Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at Week 52
percentage of participantsApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Extension Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at Week 524.3 (0.5 to 14.5)10.0 (3.3 to 21.8)13.8 (6.1 to 25.4)14.8 (4.2 to 33.7)11.1 (2.4 to 29.2)
SecondaryExtension Study: Percentage of Participants Who Achieved a 100% Improvement (Response) in the PASI Score at Week 32

A participant was classified as having achieved a PASI-100 response if the PASI score was reduced by at least 100% from baseline. The PASI score was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 to Week 32

No measurements were reported for this outcome.

SecondaryExtension Study: Percentage of Participants Who Achieved a 100% Improvement (Response) in the PASI Score at Week 40

A participant was classified as having achieved a PASI-100 response if the PASI score was reduced by at least 100% from baseline. The PASI score was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 to Week 40

No measurements were reported for this outcome.

SecondaryExtension Study: Percentage of Participants Who Achieved a 100% Improvement (Response) in the PASI Score at Week 52

A participant was classified as having achieved a PASI-100 response if the PASI score was reduced by at least 100% from baseline. The PASI score was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 to Week 52

No measurements were reported for this outcome.

SecondaryExtension Study: Time to Achieve PASI-75 During the Extension Study

For PASI-75 responders in the extension study, time to achieve PASI-75 was defined as the time interval, inclusive between the date of randomization (Day 1) and the date of the first assessment where PASI-75 was achieved.

Time frame:
Week 0 to Week 52

No measurements were reported for this outcome.

SecondaryExtension Study: Time to Achieve PASI-50 During the Extension Study

For PASI-50 responders in the extension study, time to achieve PASI-50 was defined as the time interval, inclusive between the date of randomization (Day 1) and the date of the first assessment where PASI-50 was achieved.

Time frame:
Week 0 to Week 52

No measurements were reported for this outcome.

SecondaryExtension Study: Time to Achieve PASI-90 During the Extension Study

For PASI-90 responders in the extension study, time to achieve PASI-90 was defined as the time interval, inclusive between the date of randomization (Day 1) and the date of the first assessment where PASI-90 was achieved.

Time frame:
Week 0 to Extension study

No measurements were reported for this outcome.

SecondaryExtension Study: Time to Achieve PASI-100 During the Extension Study

For PASI-100 responders in the extension study, time to achieve PASI-100 was defined as the time interval, inclusive between the date of randomization (Day 1) and the date of the first assessment where PASI-100 was achieved.

Time frame:
Week 0 to Extension Study

No measurements were reported for this outcome.

Other pre-specifiedExtension Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at Week 32

The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less severe disease.

Time frame:
Week 0 to Week 32
Reported as:
Number · percentage of participants
Extension Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at Week 32
percentage of participantsApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Extension Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at Week 3223.4 (12.3 to 38.0)26 (14.6 to 40.3)44.8 (31.7 to 58.5)33.3 (16.5 to 54.0)59.3 (38.8 to 77.6)
Other pre-specifiedExtension Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at Week 40

The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less disease.

Time frame:
Week 0 to Week 40
Reported as:
Number · percentage of participants
Extension Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at Week 40
percentage of participantsApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Extension Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at Week 4023.4 (12.3 to 38.0)18.0 (8.6 to 31.4)29.3 (18.1 to 42.7)29.6 (13.8 to 50.2)37.0 (19.4 to 57.6)
Other pre-specifiedExtension Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at Week 52

The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less severe disease.

Time frame:
Week 0 to Week 52
Reported as:
Number · percentage of participants
Extension Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at Week 52
percentage of participantsApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Extension Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at Week 5212.8 (4.8 to 25.7)10.0 (3.3 to 21.8)22.4 (12.5 to 35.3)33.3 (16.5 to 54.0)22.2 (8.6 to 42.3)
SecondaryExtension Study: Percent Change in PASI Score at Week 32

The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score

Time frame:
Week 0 to Week 32
Reported as:
Mean · percent change
Extension Study: Percent Change in PASI Score at Week 32
percent changeApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Extension Study: Percent Change in PASI Score at Week 32-51.0 ± 34.10-63.1 ± 27.01-72.7 ± 20.97-64.0 ± 25.16-69.2 ± 27.60
SecondaryExtension Study: Percent Change in PASI Score at Week 40

The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score

Time frame:
Week 0 to Week 40
Reported as:
Mean · percent change
Extension Study: Percent Change in PASI Score at Week 40
percent changeApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Extension Study: Percent Change in PASI Score at Week 40-55.9 ± 29.63-63.3 ± 27.26-71.1 ± 18.91-64.5 ± 27.05-71.7 ± 24.53
SecondaryExtension Study: Percent Change in PASI Score at Week 52

The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score

Time frame:
Week 0 to Week 52
Reported as:
Mean · percent change
Extension Study: Percent Change in PASI Score at Week 52
percent changeApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Extension Study: Percent Change in PASI Score at Week 52-55.1 ± 23.50-58.9 ± 30.65-65.3 ± 29.86-62.7 ± 29.49-62.0 ± 28.28
SecondaryExtension Study: Shift Change (1 or More Points on a 0 to 5 Point Scale) in Static Physician Global Assessment (sPGA) at Week 32

Physician Global Assessment (sPGA) was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA is a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the subject and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling. Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3).

Time frame:
Week 0 to Week 32

No measurements were reported for this outcome.

SecondaryExtension Study: Shift Change (1 or More Points on a 0 to 5 Point Scale) in Static Physician Global Assessment (sPGA) at Week 40

Physician Global Assessment (sPGA) was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA is a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the subject and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling. Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3).

Time frame:
Week 0 to Week 40

No measurements were reported for this outcome.

SecondaryExtension Study: Shift Change (1 or More Points on a 0 to 5 Point Scale) in Static Physician Global Assessment (sPGA) at Week 52

Physician Global Assessment (sPGA) was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA is a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the subject and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling. Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3).

Time frame:
Week 0 to Week 52

No measurements were reported for this outcome.

SecondaryExtension Study: Percent Change From Baseline in the Affected BSA at Week 32

The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.

Time frame:
Week 0 to Week 32
Reported as:
Mean · percent change
Extension Study: Percent Change From Baseline in the Affected BSA at Week 32
percent changeApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Extension Study: Percent Change From Baseline in the Affected BSA at Week 32-47.1 ± 45.62-65.1 ± 30.42-75.3 ± 20.19-62.6 ± 29.48-66.7 ± 34.50
SecondaryExtension Study: Percent Change From Baseline in the Affected BSA at Week 40

The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.

Time frame:
Week 0 to Week 40
Reported as:
Mean · percent change
Extension Study: Percent Change From Baseline in the Affected BSA at Week 40
percent changeApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Extension Study: Percent Change From Baseline in the Affected BSA at Week 40-55.4 ± 33.33-65.4 ± 27.33-74.3 ± 17.98-66.2 ± 27.19-68.0 ± 32.83
SecondaryExtension Study: Percent Change From Baseline in the Affected BSA at Week 52

The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.

Time frame:
Week 0 to Week 52
Reported as:
Mean · percent change
Extension Study: Percent Change From Baseline in the Affected BSA at Week 52
percent changeApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Extension Study: Percent Change From Baseline in the Affected BSA at Week 52-53.1 ± 30.33-58.3 ± 48.88-67.3 ± 32.56-67.4 ± 28.29-64.9 ± 31.26
SecondaryExtension Study: Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 32

The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis.

Time frame:
Week 0 to Week 32
Reported as:
Mean · units on a scale
Extension Study: Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 32
units on a scaleApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Extension Study: Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 32-6.5 ± 6.13-7.5 ± 6.20-6.0 ± 5.02-8.1 ± 7.165.5 ± 5.63
SecondaryExtension Study: Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 40

The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis.

Time frame:
Week 0 to Week 40
Reported as:
Mean · units on a scale
Extension Study: Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 40
units on a scaleApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Extension Study: Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 40-5.5 ± 6.42-6.6 ± 5.92-6.4 ± 4.51-7.1 ± 7.54-5.9 ± 5.03
SecondaryExtension Study: Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 52

The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis.

Time frame:
Week 0 to Week 52
Reported as:
Mean · units on a scale
Extension Study: Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 52
units on a scaleApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Extension Study: Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 52-5.8 ± 7.11-6.1 ± 5.14-5.6 ± 4.72-6.8 ± 7.16-4.9 ± 5.05
SecondaryExtension Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Mental Component Summary Score at Week 32

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

Time frame:
Week 0 to Week 32
Reported as:
Mean · units on a scale
Extension Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Mental Component Summary Score at Week 32
units on a scaleApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Extension Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Mental Component Summary Score at Week 325.2 ± 9.453.8 ± 8.262.9 ± 7.804.6 ± 11.932.8 ± 9.64
SecondaryExtension Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Physical Component Summary Score (PCS) at Week 32

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

Time frame:
Week 0 to Week 32
Reported as:
Mean · units on a scale
Extension Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Physical Component Summary Score (PCS) at Week 32
units on a scaleApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Extension Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Physical Component Summary Score (PCS) at Week 321.4 ± 5.262.6 ± 6.671.8 ± 7.583.1 ± 9.441.5 ± 8.46
SecondaryExtension Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Mental Component Summary Score at Week 40

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

Time frame:
Week 0 to Week 40
Reported as:
Mean · units on a scale
Extension Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Mental Component Summary Score at Week 40
units on a scaleApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Extension Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Mental Component Summary Score at Week 405.4 ± 10.644.8 ± 8.951.7 ± 7.182.9 ± 12.243.8 ± 8.71
SecondaryExtension Study: Change From Baseline in Medical Outcome Study Short Form,SF-36, Version 2; Physical Component Summary Score at Week 40

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

Time frame:
Week 0 to Week 40
Reported as:
Mean · units on a scale
Extension Study: Change From Baseline in Medical Outcome Study Short Form,SF-36, Version 2; Physical Component Summary Score at Week 40
units on a scaleApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Extension Study: Change From Baseline in Medical Outcome Study Short Form,SF-36, Version 2; Physical Component Summary Score at Week 40-0.2 ± 8.401.6 ± 7.771.7 ± 7.343.2 ± 10.891.8 ± 6.20
SecondaryExtension Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Mental Component Summary Score at Week 52

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

Time frame:
Week 0 to Week 52
Reported as:
Mean · units on a scale
Extension Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Mental Component Summary Score at Week 52
units on a scaleApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Extension Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Mental Component Summary Score at Week 525.1 ± 11.564.1 ± 9.812.4 ± 7.914.7 ± 12.183.4 ± 7.49
SecondaryExtension Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Physical Component Summary Score at Week 52

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value..

Time frame:
Week 0 to Week 52
Reported as:
Mean · units on a scale
Extension Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Physical Component Summary Score at Week 52
units on a scaleApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Extension Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Physical Component Summary Score at Week 521.2 ± 7.791.2 ± 5.502.0 ± 6.813.4 ± 12.840.3 ± 6.90
SecondaryExtension Study: Dose-response Relationship Using the Percent Reduction of PASI Scores at Week 52

Dose response relationship using percent reduction in PASI scores across dose groups at Week 52 compared to Week 0

Time frame:
Week 0 to Week 52

No measurements were reported for this outcome.

SecondaryExtension Study: Time to Loss of Response During the Treatment Phase of the Extension Study.

Time to 50% loss of the maximal improvement (achieved in either the core study or the extension study) during the treatment phase of the extension study, in participants who achieved ≥ PASI-50 in either the core study or during the treatment phase of the extension study

Time frame:
Week 0 to 52

No measurements were reported for this outcome.

SecondaryTime to Loss of 50% of the PASI Response During the Observational Follow-up Phase Relative to the End of Treatment (Participants Who Had at Least a PASI-50 Response at the End of Treatment Phase)

Time to loss of response was modified to be 50% loss in the PASI response observed at the end of treatment for participants who achieved at least a PASI-50 at the end of treatment. This definition was changed since participants may have already lost their maximal PASI response prior to enrollment into the Observation Follow-up Phase. Included all participants that enrolled into the observational follow-up phase after the treatment phase.

Time frame:
Up to 4 weeks after the last dose
Reported as:
Median · weeks
Time to Loss of 50% of the PASI Response During the Observational Follow-up Phase Relative to the End of Treatment (Participants Who Had at Least a PASI-50 Response at the End of Treatment Phase)
weeksApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 20mg BIDPlacebo-Apremilast 30 mg BID
Time to Loss of 50% of the PASI Response During the Observational Follow-up Phase Relative to the End of Treatment (Participants Who Had at Least a PASI-50 Response at the End of Treatment Phase)NA (4.3 to NA)NA (4.1 to NA)NA (4.3 to NA)NA (NA to NA)5.3 (5.3 to NA)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAE) in the Placebo Controlled Phase

An AE was any noxious, unintended, or untoward medical occurrence, that may appear or worsen in a participant during the course of study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above. An AE is a treatment emergent AE if the AE start date is on or after the date of the first dose of study drug and no later than 28 days after the last dose.

Time frame:
Week 0 to Week 16; up to data cut off of 21 July 2011
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (TEAE) in the Placebo Controlled Phase
participantsPlaceboApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BID
Any treatment emergent AE57596772
Any drug-related TEAE11202332
Any severe TEAE3155
Any serious TEAE2034
Any serious drug-related0000
≥ 1 TEAE leading to drug interruption4336
≥ 1 TEAE leading to drug withdrawal52812
≥ 1 TEAE leading to death1000
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAE) in the Apremilast Exposure Period

An AE was any noxious, unintended, or untoward medical occurrence, that may appear or worsen in a participant during the course of study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above. An AE is a treatment emergent AE if the AE start date is on or after the date of the first dose of study drug and no later than 28 days after the last dose.

Time frame:
Week 0-88; up to data cut off of 21 July 2011
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (TEAE) in the Apremilast Exposure Period
participantsApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BID
Any treatment emergent AE6797110
Any drug-related TEAE233145
Any severe TEAE3913
Any serious TEAE186
Any serious drug-related010
≥ 1 TEAE leading to drug interruption3119
≥ 1 TEAE leading to drug withdrawal51115
≥ 1 TEAE leading to death000
SecondaryCore Study: Time to Achieve a PASI-50 Response During the Placebo Controlled Phase

For PASI-50 responders in the placebo-controlled period weeks 0-16, time to achieve PASI-50 was defined as the time interval, inclusive between the date of randomization (day 1) and the date of the first assessment where PASI-50 was achieved.

Time frame:
Week 0 to 16
Reported as:
Median · weeks
Core Study: Time to Achieve a PASI-50 Response During the Placebo Controlled Phase
weeksPlacebo BIDApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BID
Core Study: Time to Achieve a PASI-50 Response During the Placebo Controlled Phase6.5 (2.1 to 16.9)5.9 (1.9 to 16.7)6.0 (2.1 to 16.4)4.3 (1.9 to 16.7)
SecondaryCore Study: Time to Achieve a PASI-75 Response During the Placebo Controlled Phase

For PASI-75 responders in the placebo-controlled period Weeks 0-16, time to achieve PASI-75 was defined as the time interval, inclusive between the date of randomization (day 1) and the date of the first assessment where PASI-75 is achieved.

Time frame:
Weeks 0 to 16
Reported as:
Median · weeks
Core Study: Time to Achieve a PASI-75 Response During the Placebo Controlled Phase
weeksPlacebo BIDApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BID
Core Study: Time to Achieve a PASI-75 Response During the Placebo Controlled Phase8.1 (3.9 to 17.1)10.0 (4.0 to 16.0)11.9 (2.1 to 17.0)6.3 (3.7 to 16.7)
SecondaryCore Study: Time to Achieve a PASI-90 Response During the Placebo Controlled Phase

For PASI-90 responders in the placebo-controlled period weeks 0-16, time to achieve PASI-90 was the time interval, inclusive, between the date of randomization (day 1) and the date of the first assessment where PASI-90 was achieved.

Time frame:
Weeks 0 to 16

No measurements were reported for this outcome.

SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAE) in the Apremilast Exposure Period

An AE was any noxious, unintended, or untoward medical occurrence, that may appear or worsen in a participant during the course of study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above. An AE is a treatment emergent AE if the AE start date is on or after the date of the first dose of study drug and no later than 28 days after the last dose.

Time frame:
Week 0 to 6 years of study treatment; maximum duration of exposure was 314.6 weeks
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (TEAE) in the Apremilast Exposure Period
participantsApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BID
Any treatment emergent AE6797111
Any drug-related TEAE233246
Any severe TEAE41014
Any serious TEAE296
Any serious drug-related010
≥ 1 TEAE leading to drug interruption31110
≥ 1 TEAE leading to drug withdrawal51116
≥ 1 TEAE leading to death000
SecondaryLTE Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at 18 Months

PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 to Month 18
Reported as:
Number · percentage of participants
LTE Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at 18 Months
percentage of participantsApremilast 10mg BIDPlacebo-Apremilast 20mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at 18 Months60.0 (14.7 to 94.7)0.0 (0.0 to 60.2)40.0 (12.2 to 73.8)0.0 (0.0 to 60.2)50.0 (18.7 to 81.3)
SecondaryLTE Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at 2 Years

PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 to Month 24
Reported as:
Number · percentage of participants
LTE Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at 2 Years
percentage of participantsApremilast 10mg BIDPlacebo-Apremilast 20mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at 2 Years20.0 (0.5 to 71.6)0.0 (0.0 to 60.2)30.0 (6.7 to 65.2)25.0 (0.6 to 80.6)50.0 (18.7 to 81.3)
SecondaryLTE Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at 3 Years

PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 to Month 36
Reported as:
Number · percentage of participants
LTE Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at 3 Years
percentage of participantsApremilast 10mg BIDPlacebo-Apremilast 20mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at 3 Years60.0 (14.7 to 94.7)25.0 (0.6 to 80.6)10.0 (0.3 to 44.5)0.0 (0.0 to 60.2)30.0 (6.7 to 65.2)
SecondaryLTE Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at 4 Years

PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 to Month 48
Reported as:
Number · percentage of participants
LTE Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at 4 Years
percentage of participantsApremilast 10mg BIDPlacebo-Apremilast 20mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at 4 Years40.0 (5.3 to 85.3)0.0 (0.0 to 60.2)0 (0.0 to 30.8)25.0 (0.6 to 80.6)30.0 (6.7 to 65.2)
SecondaryLTE Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at 18 Months

PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 to Month 18
Reported as:
Number · percentage of participants
LTE Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at 18 Months
percentage of participantsApremilast 10mg BIDPlacebo-Apremilast 20mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at 18 Months100.0 (47.8 to 100.0)50.0 (6.8 to 93.2)70.0 (34.8 to 93.3)50.0 (6.8 to 93.2)100 (69.2 to 100.0)
SecondaryLTE Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at 2 Years

PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 to Month 24
Reported as:
Number · percentage of participants
LTE Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at 2 Years
percentage of participantsApremilast 10mg BIDPlacebo-Apremilast 20mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at 2 Years60.0 (14.7 to 94.7)50.0 (6.8 to 93.2)50.0 (18.7 to 81.3)25.0 (0.6 to 80.6)90.0 (55.5 to 99.7)
SecondaryLTE Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at 3 Years

PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 to Month 36
Reported as:
Number · percentage of participants
LTE Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at 3 Years
percentage of participantsApremilast 10mg BIDPlacebo-Apremilast 20mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at 3 Years60.0 (14.7 to 94.7)50.0 (6.8 to 93.2)30.0 (6.7 to 65.2)50.0 (6.8 to 93.2)60.0 (26.2 to 87.8)
SecondaryLTE Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at 4 Years

PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 to Month 48
Reported as:
Number · percentage of participants
LTE Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at 4 Years
percentage of participantsApremilast 10mg BIDPlacebo-Apremilast 20mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at 4 Years40.0 (5.3 to 85.3)25.0 (0.6 to 80.6)20.0 (2.5 to 55.6)25.0 (0.6 to 80.6)40.0 (12.2 to 73.8)
SecondaryLTE Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at 18 Months

PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 76 of the long-term extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 to Month 18
Reported as:
Number · percentage of participants
LTE Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at 18 Months
percentage of participantsApremilast 10mg BIDPlacebo-Apremilast 20mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at 18 Months0.0 (0.0 to 52.2)0.0 (0.0 to 60.2)10.0 (0.3 to 44.5)0.0 (0.0 to 60.2)30.0 (6.7 to 65.2)
SecondaryLTE Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at 2 Years

PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 100 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 to Month 24
Reported as:
Number · percentage of participants
LTE Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at 2 Years
percentage of participantsApremilast 10mg BIDPlacebo-Apremilast 20mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at 2 Years0.0 (0.0 to 52.2)0 (0.0 to 60.2)10.0 (0.3 to 44.5)0.0 (0.0 to 60.2)30.0 (6.7 to 65.2)
SecondaryLTE Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at 3 Years

PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 148 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 to Month 36
Reported as:
Number · percentage of participants
LTE Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at 3 Years
percentage of participantsApremilast 10mg BIDPlacebo-Apremilast 20mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at 3 Years20.0 (0.5 to 71.6)0.0 (0.0 to 60.2)10.0 (0.3 to 44.5)0.0 (0.0 to 60.2)20.0 (2.5 to 55.6)
SecondaryLTE Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at 4 Years

PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 196 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 to Month 48
Reported as:
Number · percentage of participants
LTE Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at 4 Years
percentage of participantsApremilast 10mg BIDPlacebo-Apremilast 20mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at 4 Years0.0 (0.0 to 52.2)0.0 (0.0 to 60.2)0.0 (0.0 to 30.8)0.0 (0.0 to 60.2)20.0 (2.5 to 55.6)
SecondaryLTE Study: Percentage of Participants Who Achieved a 100% Improvement (Response) in the PASI Score at 18 Months, 2 Years, 3 Years and 4 Years

PASI-100 response is the percentage of participants who achieved at a 100% reduction (improvement) from baseline in PASI score of the long-term extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).

Time frame:
Week 0 to Month 48

No measurements were reported for this outcome.

SecondaryLTE Study: Percent Change From Baseline in PASI Score at 18 Months

The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score

Time frame:
Week 0 to Month 18
Reported as:
Mean · percent change
LTE Study: Percent Change From Baseline in PASI Score at 18 Months
percent changeApremilast 10mg BIDPBO-Apremilast 20mg BIDApremilast 20mg BIDPBO-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Percent Change From Baseline in PASI Score at 18 Months-71.8 ± 14.84-60.5 ± 9.19-65.3 ± 21.28-50.0 ± 12.83-77.3 ± 17.77
SecondaryLTE Study: Percent Change From Baseline in PASI Score at 2 Years

The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score

Time frame:
Week 0 to Month 24
Reported as:
Mean · percent change
LTE Study: Percent Change From Baseline in PASI Score at 2 Years
percent changeApremilast 10mg BIDPBO-Apremilast 20mg BIDApremilast 20mg BIDPBO-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Percent Change From Baseline in PASI Score at 2 Years-57.8 ± 19.51-64.5 ± 3.54-65.9 ± 21.22-46.0 ± 23.11-78.4 ± 16.60
SecondaryLTE Study: Percent Change From Baseline in PASI Score at 3 Years

The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score

Time frame:
Week 0 to Month 36
Reported as:
Mean · percent change
LTE Study: Percent Change From Baseline in PASI Score at 3 Years
percent changeApremilast 10mg BIDPBO-Apremilast 20mg BIDApremilast 20mg BIDPBO-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Percent Change From Baseline in PASI Score at 3 Years-87.7 ± 5.69-69.0 ± 22.63-48.8 ± 29.69-48.0 ± 14.12-80.0 ± 17.88
SecondaryLTE Study: Percent Change From Baseline in PASI Score at 4 Years

The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score

Time frame:
Week 0 to Month 48
Reported as:
Mean · percent change
LTE Study: Percent Change From Baseline in PASI Score at 4 Years
percent changeApremilast 10mg BIDPBO-Apremilast 20mg BIDApremilast 20mg BIDPBO-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Percent Change From Baseline in PASI Score at 4 Years-82.5 ± 0.71-52.0 ± 29.70-54.3 ± 20.55-80.0 ± NA-85.0 ± 17.80
SecondaryCore Study: Shift Change (1 or More Points on a 0 to 5 Point Scale) in Static Physician Global Assessment (sPGA) at Month 18, and Years 2, 3 and 4

Physician Global Assessment (sPGA) was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA is a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling. Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3).

Time frame:
Week 0 to Week 196

No measurements were reported for this outcome.

SecondaryLTE Study: Percent Change From Baseline in the Percent of the Affected Body Surface Area (BSA) at 18 Months

The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.

Time frame:
Week 0 to Month 18
Reported as:
Mean · percent change
LTE Study: Percent Change From Baseline in the Percent of the Affected Body Surface Area (BSA) at 18 Months
percent changeApremilast 10mg BIDPlacebo-Apremilast 20 mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Percent Change From Baseline in the Percent of the Affected Body Surface Area (BSA) at 18 Months-71.1 ± 16.82-73.9 ± 1.61-74.2 ± 18.83-44.2 ± 26.79-76.7 ± 23.70
SecondaryLTE Study: Percent Change From Baseline in the Percent of the Affected Body Surface Area (BSA) at 2 Years

The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.

Time frame:
Week 0 to Month 24
Reported as:
Mean · percent change
LTE Study: Percent Change From Baseline in the Percent of the Affected Body Surface Area (BSA) at 2 Years
percent changeApremilast 10mg BIDPlacebo-Apremilast 20 mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Percent Change From Baseline in the Percent of the Affected Body Surface Area (BSA) at 2 Years-64.7 ± 15.95-66.2 ± 3.62-74.5 ± 15.86-24.7 ± 49.99-74.5 ± 21.66
SecondaryLTE Study: Percent Change From Baseline in the Percent of the Affected Body Surface Area (BSA) at 3 Years

The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.

Time frame:
Week 0 to Month 36
Reported as:
Mean · percent change
LTE Study: Percent Change From Baseline in the Percent of the Affected Body Surface Area (BSA) at 3 Years
percent changeApremilast 10mg BIDPlacebo-Apremilast 20 mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Percent Change From Baseline in the Percent of the Affected Body Surface Area (BSA) at 3 Years-86.1 ± 3.00-63.4 ± 25.31-58.4 ± 29.80-39.1 ± 39.39-78.5 ± 21.02
SecondaryLTE Study: Percent Change From Baseline in the Percent of the Affected Body Surface Area (BSA) at 4 Years

The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.

Time frame:
Week 0 to Month 48
Reported as:
Mean · percent change
LTE Study: Percent Change From Baseline in the Percent of the Affected Body Surface Area (BSA) at 4 Years
percent changeApremilast 10mg BIDPlacebo-Apremilast 20 mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Percent Change From Baseline in the Percent of the Affected Body Surface Area (BSA) at 4 Years-75.0 ± 0.00-50.6 ± 18.48-72.4 ± 14.95-75.0 ± NA-86.1 ± 18.58
SecondaryLTE Study: Median Percent Change From Baseline in the Affected Body Surface Area (BSA) at 18 Months

The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.

Time frame:
Week 0 to Month 18
Reported as:
Median · percent change
LTE Study: Median Percent Change From Baseline in the Affected Body Surface Area (BSA) at 18 Months
percent changeApremilast 10mg BIDPlacebo-Apremilast 20 mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Median Percent Change From Baseline in the Affected Body Surface Area (BSA) at 18 Months-78.6 (-83.3 to -42.9)-73.9 (-75.0 to -72.7)-73.3 (-95.3 to -47.3)-49.2 (-69.4 to -9.1)-86.4 (-100.0 to -30.8)
SecondaryLTE Study: Median Percent Change From Baseline in the Affected Body Surface Area (BSA) at 2 Years

The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.

Time frame:
Week 0 to Month 24
Reported as:
Median · percent change
LTE Study: Median Percent Change From Baseline in the Affected Body Surface Area (BSA) at 2 Years
percent changeApremilast 10mg BIDPlacebo-Apremilast 20 mg BIDApremilast 20mg BIDApremilast 30 mg BIDPlacebo-Apremilast 30 mg BID
LTE Study: Median Percent Change From Baseline in the Affected Body Surface Area (BSA) at 2 Years-60.5 (-91.7 to -50.0)-66.2 (-68.8 to -63.6)-75.0 (-95.5 to -56.3)-41.5 (-61.1 to 45.5)-77.4 (-100.0 to -42.9)
SecondaryLTE Study: Median Percent Change From Baseline in the Affected Body Surface Area (BSA) at 3 Years

The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.

Time frame:
Week 0 to Month 36
Reported as:
Median · percent change
LTE Study: Median Percent Change From Baseline in the Affected Body Surface Area (BSA) at 3 Years
percent changeApremilast 10mg BIDPlacebo-Apremilast 20 mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Median Percent Change From Baseline in the Affected Body Surface Area (BSA) at 3 Years-85.7 (-89.3 to -83.3)-63.4 (-81.3 to -45.5)-60.9 (-95.5 to -7.7)-52.2 (-70.0 to 18.2)-81.0 (-100.0 to -50.0)
SecondaryLTE Study: Median Percent Change From Baseline in the Affected Body Surface Area (BSA) at 4 Years

The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.

Time frame:
Week 0 to Month 48
Reported as:
Median · percent change
LTE Study: Median Percent Change From Baseline in the Affected Body Surface Area (BSA) at 4 Years
percent changeApremilast 10mg BIDPlacebo-Apremilast 20 mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Median Percent Change From Baseline in the Affected Body Surface Area (BSA) at 4 Years-75.0 (-75.0 to -75.0)-50.6 (-63.6 to -37.5)-73.5 (-86.4 to -56.3)-75.0 (-75.0 to -75.0)-91.9 (-100.0 to -60.7)
SecondaryLTE Study: Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at 18 Months

The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis.

Time frame:
Week 0 to Month 18
Reported as:
Mean · units on a scale
LTE Study: Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at 18 Months
units on a scaleApremilast 10mg BIDPlacebo-Apremilast 20mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at 18 Months——-6.5 ± 4.95——
SecondaryLTE Study: Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at 2 Years

The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis.

Time frame:
Week 0 to Month 24
Reported as:
Mean · units on a scale
LTE Study: Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at 2 Years
units on a scaleApremilast 10mg BIDPlacebo-Apremilast 20mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at 2 Years-5.2 ± 5.17-13.5 ± 16.26-5.9 ± 5.70-1.8 ± 2.36-6.8 ± 4.27
SecondaryLTE Study: Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at 3 Years

The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis.

Time frame:
Week 0 to Month 36
Reported as:
Mean · units on a scale
LTE Study: Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at 3 Years
units on a scaleApremilast 10mg BIDPlacebo-Apremilast 20mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at 3 Years-11.7 ± 5.03-3.0 ± NA-4.2 ± 3.37-2.0 ± 3.56-6.0 ± 6.03
SecondaryLTE Study: Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at 4 Years

The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis.

Time frame:
Week 0 to Month 48
Reported as:
Mean · units on a scale
LTE Study: Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at 4 Years
units on a scaleApremilast 10mg BIDPlacebo-Apremilast 20mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at 4 Years-6.0 ± 5.66-9.0 ± 11.31-3.5 ± 1.00-7.0 ± NA-10.3 ± 5.13
SecondaryLTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Mental Component Summary Score at 18 Months

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

Time frame:
Week 0 to Month 18
Reported as:
Mean · units on a scale
LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Mental Component Summary Score at 18 Months
units on a scaleApremilast 10mg BIDPlacebo-Apremilast 20mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Mental Component Summary Score at 18 Months——-2.8 ± 15.33——
SecondaryLTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Mental Component Summary Score at 2 Years

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

Time frame:
Week 0 to Month 24
Reported as:
Mean · units on a scale
LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Mental Component Summary Score at 2 Years
units on a scaleApremilast 10mg BIDPlacebo-Apremilast 20mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Mental Component Summary Score at 2 Years5.0 ± 8.602.0 ± 14.755.2 ± 9.574.5 ± 8.750.2 ± 11.21
SecondaryLTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Mental Component Summary Score at 3 Years

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

Time frame:
Week 0 to Month 36
Reported as:
Mean · units on a scale
LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Mental Component Summary Score at 3 Years
units on a scaleApremilast 10mg BIDPlacebo-Apremilast 20mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Mental Component Summary Score at 3 Years6.0 ± 8.44-2.7 ± NA3.6 ± 7.912.1 ± 10.792.4 ± 3.75
SecondaryLTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Mental Component Summary Score at 4 Years

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

Time frame:
Week 0 to Month 48
Reported as:
Mean · units on a scale
LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Mental Component Summary Score at 4 Years
units on a scaleApremilast 10mg BIDPlacebo-Apremilast 20mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Mental Component Summary Score at 4 Years-1.1 ± 19.834.1 ± 10.07-1.0 ± 1.5017.6 ± NA1.2 ± 6.54
SecondaryLTE Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Physical Component Summary Score at 18 Months

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

Time frame:
Week 0 to Month 18
Reported as:
Mean · units on a scale
LTE Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Physical Component Summary Score at 18 Months
units on a scaleApremilast 10mg BIDPlacebo-Apremilast 20mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Physical Component Summary Score at 18 Months——10.2 ± 11.84——
SecondaryLTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Physical Component Summary Score at 2 Years

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

Time frame:
Week 0 to Month 24
Reported as:
Mean · units on a scale
LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Physical Component Summary Score at 2 Years
units on a scaleApremilast 10mg BIDPlacebo-Apremilast 20mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Physical Component Summary Score at 2 Years4.1 ± 9.153.7 ± 1.871.0 ± 7.132.4 ± 8.075.0 ± 6.33
SecondaryLTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Physical Component Summary Score at 3 Years

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

Time frame:
Week 0 to Month 36
Reported as:
Mean · units on a scale
LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Physical Component Summary Score at 3 Years
units on a scaleApremilast 10mg BIDPlacebo-Apremilast 20mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Physical Component Summary Score at 3 Years6.6 ± 9.481.0 ± NA-0.1 ± 6.054.4 ± 7.494.2 ± 9.27
SecondaryLTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Physical Component Summary Score at 4 Years

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.

Time frame:
Week 0 to Month 48
Reported as:
Mean · units on a scale
LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Physical Component Summary Score at 4 Years
units on a scaleApremilast 10mg BIDPlacebo-Apremilast 20mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Physical Component Summary Score at 4 Years1.4 ± 16.062.0 ± 0.79-4.1 ± 4.9510.2 ± NA9.4 ± 6.10
Other pre-specifiedLTE Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at 18 Months

The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less severe disease

Time frame:
Week 0 to Month 18
Reported as:
Number · percentage of participants
LTE Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at 18 Months
percentage of participantsApremilast 10mg BIDPlacebo-Apremilast 20 mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at 18 Months60.0 (14.7 to 94.7)0.0 (0.0 to 60.2)20.0 (2.5 to 55.6)25.0 (0.6 to 80.6)60.0 (26.2 to 87.8)
Other pre-specifiedLTE Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at 2 Years

The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less severe disease

Time frame:
Week 0 to Month 24
Reported as:
Number · percentage of participants
LTE Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at 2 Years
percentage of participantsApremilast 10mg BIDPlacebo-Apremilast 20 mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at 2 Years20.0 (0.5 to 71.6)0.00 (0.0 to 60.2)10.0 (0.3 to 44.5)25.0 (0.6 to 80.6)40.0 (12.2 to 73.8)
Other pre-specifiedLTE Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at 3 Years

The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less severe disease

Time frame:
Week 0 and month 36
Reported as:
Number · percentage of participants
LTE Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at 3 Years
percentage of participantsApremilast 10mg BIDPlacebo-Apremilast 20 mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at 3 Years60.0 (14.7 to 94.7)0.0 (0.0 to 60.2)0 (0.0 to 30.8)25.0 (0.6 to 80.6)30.0 (6.7 to 65.2)
Other pre-specifiedLTE Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at 4 Years

The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less severe disease

Time frame:
Week 0 to Month 48
Reported as:
Number · percentage of participants
LTE Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at 4 Years
percentage of participantsApremilast 10mg BIDPlacebo-Apremilast 20 mg BIDApremilast 20mg BIDPlacebo-Apremilast 30 mg BIDApremilast 30 mg BID
LTE Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at 4 Years20.0 (0.5 to 71.6)0.0 (0.0 to 60.2)0.0 (0.0 to 30.8)25.0 (0.6 to 80.6)30.0 (6.7 to 65.2)

Adverse events

Collected over Adverse Events are reported for the 16-week placebo-controlled phase and up to the LTE period, (6 years) for all participants who were randomized or re-randomized to apremilast at any time during the core, the extension or the long term extension study.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Weeks 0-16)—2/88 (2.3%)35/88 (39.8%)
Apremilast 10mg BID (Weeks 0-16)—0/89 (0%)42/89 (47.2%)
Apremilast 20mg BID (Weeks 0-16)—3/87 (3.4%)45/87 (51.7%)
Apremilast 30mg BID (Weeks 0-16)—4/88 (4.5%)55/88 (62.5%)
Apremilast 10mg BID (APR Exposure Period) Years 0-6—2/89 (2.2%)52/89 (58.4%)
Apremilast 20mg BID (APR Exposure Period) Years 0-6—9/121 (7.4%)66/121 (54.5%)
Apremilast 30mg BID (APR Exposure Period) Years 0-6—9/124 (7.3%)85/124 (68.5%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventPlacebo (Weeks 0-16)Apremilast 10mg BID (Weeks 0-16)Apremilast 20mg BID (Weeks 0-16)Apremilast 30mg BID (Weeks 0-16)Apremilast 10mg BID (APR Exposure Period) Years 0-6Apremilast 20mg BID (APR Exposure Period) Years 0-6Apremilast 30mg BID (APR Exposure Period) Years 0-6
PregnancyPregnancy, puerperium and perinatal conditions0/880/890/872/880/890/1212/124
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/880/890/871/880/890/1212/124
CellulitisInfections and infestations0/880/891/870/880/891/1210/124
NephrolithiasisRenal and urinary disorders0/880/891/870/880/891/1210/124
PsoriasisSkin and subcutaneous tissue disorders0/880/891/870/880/891/1210/124
Myocardial infarctionCardiac disorders0/880/890/871/880/890/1211/124
Sudden deathGeneral disorders1/880/890/870/880/890/1210/124
Drug eruptionSkin and subcutaneous tissue disorders1/880/890/870/880/890/1210/124
BronchitisInfections and infestations0/880/890/870/881/890/1210/124
Muscle haemorrhageMusculoskeletal and connective tissue disorders0/880/890/870/881/890/1210/124
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlacebo (Weeks 0-16)Apremilast 10mg BID (Weeks 0-16)Apremilast 20mg BID (Weeks 0-16)Apremilast 30mg BID (Weeks 0-16)Apremilast 10mg BID (APR Exposure Period) Years 0-6Apremilast 20mg BID (APR Exposure Period) Years 0-6Apremilast 30mg BID (APR Exposure Period) Years 0-6
NauseaGastrointestinal disorders7/8810/8913/8717/8812/8920/12128/124
Upper respiratory tract infectionInfections and infestations4/889/8911/8714/8814/8919/12125/124
Tension headacheNervous system disorders7/883/892/8714/884/894/12118/124
DiarrhoeaGastrointestinal disorders4/886/896/8712/887/899/12117/124
NasopharyngitisInfections and infestations7/888/897/875/8810/8911/12113/124
Viral upper respiratory tract infectionInfections and infestations8/882/898/877/887/8913/12113/124
HeadacheNervous system disorders5/885/898/877/887/8913/12111/124
DyspepsiaGastrointestinal disorders2/881/895/874/881/896/1219/124
Pain in extremityMusculoskeletal and connective tissue disorders6/880/890/871/880/892/1211/124
VomitingGastrointestinal disorders1/880/893/874/881/898/1215/124

Baseline characteristics

The intent-to-treat (ITT) population consisted of all randomized participants.

Age, Continuous
Age, Continuous(years)PlaceboApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDTotal
Mean44.1 ± 13.6844.4 ± 13.9644.6 ± 12.6244.1 ± 14.6744.3 ± 13.70
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDTotal
Female35263238131
Male53635550221
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDTotal
White83828280327
Black or African American12126
Asian432413
Native Hawaiian/Pacific Islanders00101
American Indian/Alaska Native02013
Other00112
Duration of Plaque Psoriasis
Duration of Plaque Psoriasis(years)PlaceboApremilast 10mg BIDApremilast 20mg BIDApremilast 30 mg BIDTotal
Mean19.61 ± 11.63218.01 ± 12.36619.51 ± 12.15119.18 ± 12.01518.99 ± 12.004
08

Study locations

35 sites
  • Associates In Research Inc
    Fresno, California 93720, United States
  • Dermatology Associates
    Los Angeles, California 90045, United States
  • Stanford University School of Medicine
    Redwood City, California 94063, United States
  • Atlantic Skin & Cosmetic Surgery Group, PC
    Wilmington, Delaware 19810, United States
  • Renstar Medical Research
    Ocala, Florida 34471, United States
  • Atlanta Dermatology, Vein & Research Center
    Alpharetta, Georgia 30022, United States
  • NorthShore University HealthSystem
    Skokie, Illinois 60077, United States
  • Dawes/Fretzin Dermatology Group Inc
    Indianapolis, Indiana 46256, United States
  • Dermatology & Advanced Aesthetics
    Lake Charles, Louisiana 70605, United States
  • Minnesota Clinical Study Center
    Fridley, Minnesota 55432, United States
  • Central Dermatology
    Saint Louis, Missouri 63117, United States
  • UMDNJ Robert Wood Johnson
    New Brunswick, New Jersey 08901, United States
  • Wright State University
    Dayton, Ohio 45408, United States
  • Allergy, Asthma and Dermatology Research Center
    Lake Oswego, Oregon 97035, United States
  • Northwest Cutaneous Research Specialists
    Portland, Oregon 97210, United States
  • Oregon Med. Research Center, PC
    Portland, Oregon 97223, United States
  • Rivergate Dermatology Clinical Research
    Goodlettsville, Tennessee 37072, United States
  • Modern Research Associates
    Dallas, Texas 75231, United States
  • Dermatology Associates of Seattle
    Seattle, Washington 98101, United States
  • Aurora Advanced Healthcare, Inc
    Milwaukee, Wisconsin 53209, United States
  • Stratica Medical
    Edmonton, Alberta T5K 1X3, Canada
  • Dr. Lorne E. Albrecht
    Surrey, British Columbia V3R 6A7, Canada
  • Alpha Clinical Research Centre
    St. John's, Newfoundland and Labrador A1B 4S8, Canada
  • Eastern Canada Cutaneous Research Associates
    Halifax, Nova Scotia B3H 1Z4, Canada
  • Ultranova Skincare
    Barrie, Ontario L4M 6L2, Canada
  • Dermatrials Research Division
    Hamilton, Ontario L8N 1V6, Canada
  • Guenther Dermatology Research Centre
    London, Ontario N6A 3H7, Canada
  • North Bay Dermatology Centre
    North Bay, Ontario P1B 3Z7, Canada
  • Dr. Michael Robern
    Ottawa, Ontario K2G 6E2, Canada
  • K. Papp Clinical Research Inc.
    Waterloo, Ontario N2J 1C4, Canada
  • XLR8 Research
    Windsor, Ontario N8W 1E6, Canada
  • Innovaderm Research Laval Inc.
    Laval, Quebec H7S 2C6, Canada
  • Centre De Recherche Dermatologique du Qu
    MetSte-Foy, Quebec G1V 4X7, Canada
  • Innovaderm Research Inc.
    Montreal, Quebec H2K 4L5, Canada
  • International Dermatology Research, Inc.
    Montreal, Quebec H3H 1V4, Canada
09

References and documents

Publications

  • Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, Hu C, Day RM. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet. 2012 Aug 25;380(9843):738-46. doi: 10.1016/S0140-6736(12)60642-4. Epub 2012 Jun 29. PubMed 22748702 ↗
  • Ohtsuki M, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. J Dermatol. 2018 Sep;45(9):1053-1062. doi: 10.1111/1346-8138.14504. Epub 2018 Jun 15. PubMed 29905383 ↗
  • Knuckles MLF, Levi E, Soung J. Defining and treating moderate plaque psoriasis: a dermatologist survey. J Dermatolog Treat. 2018 Nov;29(7):658-663. doi: 10.1080/09546634.2018.1443200. Epub 2018 Mar 22. PubMed 29502473 ↗
  • Knuckles MLF, Levi E, Soung J. Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast. J Dermatolog Treat. 2019 Aug;30(5):430-434. doi: 10.1080/09546634.2018.1528326. Epub 2018 Nov 26. PubMed 30339049 ↗
  • Wu JJ, Pelletier C, Ung B, Tian M. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis. J Med Econ. 2019 Apr;22(4):365-371. doi: 10.1080/13696998.2019.1571500. Epub 2019 Feb 4. PubMed 30652520 ↗
  • Wang Y, Coyne K, Sofen H, Santanello N, Currie B, Zhang Z, Nograles K. Qualitative analysis and reproducibility assessment of the Scalp Itch Numeric Rating Scale among patients with moderate to severe plaque psoriasis of the scalp. J Dermatolog Treat. 2019 Dec;30(8):775-783. doi: 10.1080/09546634.2019.1577546. Epub 2019 Mar 5. PubMed 30747550 ↗
  • Strand V, Fiorentino D, Hu C, Day RM, Stevens RM, Papp KA. Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study. Health Qual Life Outcomes. 2013 May 10;11:82. doi: 10.1186/1477-7525-11-82. PubMed 23663752 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2008 to primary completion in Aug 2009, 11 months.

Results were first posted in Nov 2014, 5 years 3 months after primary completion. A results delay was requested in Jul 2013.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 11 months is close to that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2008
First posted
Oct 16, 2008
StartActual
Sep 1, 2008
Primary completionActual
Aug 1, 2009
CompletionActual
May 20, 2015
Results delay requested
Jul 26, 2013
Results first posted
Nov 13, 2014
Last update
May 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00773734
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Oct 16, 2008
Start date
Sep 1, 2008
Primary completion
Aug 1, 2009
Completion
May 20, 2015
Results posted
Nov 13, 2014
Last update
May 7, 2020

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion